Page last updated: 2024-12-05

2-chloropyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-chloropyridine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7977
CHEMBL ID509579
CHEBI ID39174
SCHEMBL ID11292442
SCHEMBL ID16637
SCHEMBL ID10993088
MeSH IDM0221267

Synonyms (65)

Synonym
STL298559
wln: t6nj bg
2-chloropyridine
nsc-4649
109-09-1
pyridine, 2-chloro-
nsc4649
.alpha.-chloropyridine
o-chloropyridine
inchi=1/c5h4cln/c6-5-3-1-2-4-7-5/h1-4
NCGC00091425-01
smr000568486
MLS001065616
ai3-19231
un2822
einecs 203-646-3
ccris 1724
nsc 4649
2-chloropyridine, 99%
alpha-chloropyridine
CHEBI:39174 ,
CHEMBL509579
FT-0664965
AKOS000119192
A801967
2-chloranylpyridine
NCGC00091425-02
2-chloro-pyridine
hsdb 8442
unii-8hmd45ayej
2-chloropyridine [un2822] [poison]
8hmd45ayej ,
ec 203-646-3
HMS3039I07
dtxcid304810
cas-109-09-1
NCGC00257172-01
tox21_303307
dtxsid8024810 ,
tox21_202283
NCGC00259832-01
SCHEMBL11292442
2-chloro pyridine
einecs 270-187-3
FT-0612018
PS-6209
2-chloropyridine-13c5
pyridine, chloro-
AM81281
BBL027569
SCHEMBL16637
2-chlorpyridine
2chloro-pyridine
2-chloropyridin
chloro-pyridine
SCHEMBL10993088
un 2822
W-108706
chloropyridine, 2-
mfcd00006228
F0001-0194
2-chloropyridine; nsc 4649; o-chloropyridine; alpha-chloropyridine
a-chloropyridine
Q209364
EN300-18341
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
monochloropyridineA chloropyridine in which only one chlorine is attached to the pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency5.01190.004023.8416100.0000AID485290
interleukin 8Homo sapiens (human)Potency42.16320.047349.480674.9780AID651758
GLI family zinc finger 3Homo sapiens (human)Potency76.95880.000714.592883.7951AID1259369
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency42.43410.003041.611522,387.1992AID1159552; AID1159553; AID1159555
aryl hydrocarbon receptorHomo sapiens (human)Potency24.33650.000723.06741,258.9301AID743085
gemininHomo sapiens (human)Potency7.30780.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1637721Glutathione reactivity assessed as thiol reactivity rate constant at 250 uM up to 72 hrs by HPLC-MS or NMR analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors.
AID1170688GSH reactivity assessed as reaction half life through transition state modeling at pH 7.42014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.
AID343398Octanol-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID343680Hexadecane-water distribution coefficient, log D at pH 7.4 by shake-flask technique2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Toward prediction of alkane/water partition coefficients.
AID1654591Substrate activity at MGST1 in rat liver microsomes assessed as reactivity rate at 50 uM incubated for 1 to 40 mins in presence of GSH by liquid chromatography/mass spectrometry2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID1149238Dissociation constant, pKa of the compound1976Journal of medicinal chemistry, Apr, Volume: 19, Issue:4
Mode of action and quantitative structure-activity correlations of tuberculostatic drugs of the isonicotinic acid hydrazide type.
AID1637723Stability of the compound assessed as half life for degradation2019MedChemComm, Feb-01, Volume: 10, Issue:2
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors.
AID1170692Reactivity of covalent reactive group using GSH reaction assessed as pseudo-first-order reaction at 37 degC by nuclear magnetic resonance spectroscopy2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors.
AID1637722Glutathione reactivity assessed as half life at 250 uM up to 72 hrs by HPLC-MS or NMR analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Design and characterization of a heterocyclic electrophilic fragment library for the discovery of cysteine-targeted covalent inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (11.11)18.7374
1990's1 (3.70)18.2507
2000's6 (22.22)29.6817
2010's15 (55.56)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.26 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index63.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]